Clinical data | |
---|---|
Trade names | Conteben |
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Oral |
ATC code | |
Identifiers | |
|
|
Synonyms | N-[4-[(Carbamothioylhydrazinylidene) methyl]phenyl]acetamide |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.002.882 |
Chemical and physical data | |
Formula | C10H12N4OS |
Molar mass | 236.29 g·mol−1 |
3D model (Jmol) | |
|
|
|
|
(what is this?) |
Thioacetazone (INN and BAN; also called amithiozone (USAN), thiocetazone, thiacetazone, thiosemicarbazone, or benzothiozane) is a pharmaceutical drug used in the treatment of tuberculosis; it has only weak activity against Mycobacterium tuberculosis and is only useful in preventing resistance to more powerful drugs such as isoniazid and rifampicin. It is never used on its own to treat tuberculosis; it is used in a similar way to ethambutol.
There is no advantage to using thioacetazone if the regimen used already contains ethambutol, but many countries in sub-Saharan Africa still use thioacetazone because it is extremely cheap. Use of thioacetazone is declining because it can cause severe (sometimes fatal) skin reactions in HIV positive patients.
One of the documented adverse effects of thioacetazone is the excessive accumalation of serum (or blood plasma) in the brain. Another is weakening of the thyroid glands. These were found in a treatment combining conteben with PAS acid p-amino-salicylic acid.